NSCLC
Conditions
Interventions
The dosage of TS-1 administers 80mg/m2/day. And, it administers for 14 days, and it takes a rest for seven days afterwards. The treatment period administers more than four courses or disease progr
Sponsors
Ehime University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically confirmed Non-Small Cell Lung Cancer 2)Advanced Stage (IV or IIIB) 3)previously treated by chemotherapy and failure 4)The case of prior Radiation therapy is accceptable. But It is necessary to pass for 4 weeks and more since last treatment and recovery adversed event 5)With measurable lesion 6)Oral intake is possible 7)20<=, years 8)Patients who have estimated life expectancy longer than 3 months 9)Performance Status(ECOG):0-2 10)Adequate organ functions 11)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients with serious infections or susupected infections with fever 2)complication of massive pericardial effusion, ascites or pleural sffusion 3)uncontrollable heart failure or Interstitial pneumonitis 4)Pregnant or lactating woman 5)Symptomatic brain metastasis 6)Hystory of active double cancer 7)poorly controled diabetes mellitus 8)Patients whose participation in the trial is judged to be inappropriate by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy (Response Rate(CR+PR),Disease Control Rate(CR+PR+SD) | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety(Adverse events), PFS, OS | — |
Countries
Japan
Outcome results
None listed